SCHEMBL6804559

SCHEMBL6804559

CCOc1cc(-c2ccc(C(=O)O)cc2)nn1CCOc1ccc(-c2ccc(OC)cc2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.43
MDM2 Q00987 2/20 0.43
MAPT P10636 1/20 0.42
GCGR P47871 1/20 0.41
GIPR P48546 1/20 0.41
RXRA P19793 2/20 0.40
CHEK1 O14757 1/20 0.40
RXRB P28702 1/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
PTPN11 Q06124 1/20 0.39
PDE4B Q07343 2/20 0.39
ERN1 O75460 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6614237 0.95 MRGPRX4 (0.45) TP53MDM2MAPTGCGRGIPR
SCHEMBL6800862 0.92 NLRP3 (0.43) MAPTGCGRGIPRERN1CYP2C9
SCHEMBL6604189 0.90 MAPT (0.43) MAPTERN1
SCHEMBL6803960 0.89 TP53 (0.43) TP53MDM2MAPTGCGRGIPR
SCHEMBL6606542 0.89 TP53 (0.47) TP53MDM2MAPTGCGRGIPR
SCHEMBL6803407 0.88 TP53 (0.44) TP53MDM2MAPTGCGRGIPR
SCHEMBL6606062 0.87 TP53 (0.46) TP53MDM2MAPTGCGRGIPR
SCHEMBL6602104 0.86 NLRP3 (0.44) MAPTGCGRGIPRMRGPRX4CYP2C9
SCHEMBL6602303 0.86 MAPK1 (0.39) MAPTGCGRGIPRMRGPRX4PDE4B
SCHEMBL6603996 0.86 TP53 (0.44) TP53MDM2MAPTGCGRGIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 TP53 35/4885MDM2 1509/4885MAPT 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.